Nakashima Marcelo Almeida, Delfrate Gabrielle, Albino Lucas Braga, Alves Gustavo Ferreira, Oliveira Junior Garcia, Fernandes Daniel
Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Acute Crit Care. 2025 Feb;40(1):46-58. doi: 10.4266/acc.002904. Epub 2025 Feb 12.
Sepsis is a life-threatening condition that affects the cardiovascular and renal systems. Severe hypotension during sepsis compromises tissue perfusion, which can lead to multiple organ dysfunction and death. Phosphodiesterase 5 (PDE5) degrades intracellular cyclic guanosine monophosphate (cGMP) levels which promotes vasodilatation in specific sites. Our previous studies show that inhibiting cGMP production in early sepsis increases mortality, implying a protective role for cGMP production. Then, we hypothesized that cGMP increased by tadalafil (PDE5 inhibitor) could improve microcirculation and prevent sepsis-induced organ dysfunction.
Rats were submitted to cecal ligation and puncture (CLP) sepsis model and treated with tadalafil (2 mg/kg, s.c.) 8 hours after the procedure. Hemodynamic, inflammatory and biochemical assessments were performed 24 hours after sepsis induction. Moreover, the effect of tadalafil on the survival of septic rats was evaluated for 5 days.
Tadalafil treatment improves basal renal blood flow during sepsis and preserves it during noradrenaline infusion. Sepsis induces hypotension, impaired response to noradrenaline, and increased cardiac and renal neutrophil infiltration, in addition to increased levels of plasma nitric oxide and lactate. None of these dysfunctions were changed by tadalafil. Additionally, tadalafil treatment did not increase the survival rate of septic rats.
Tadalafil improved microcirculation of septic animals; however, no beneficial effects were observed on macrocirculation and inflammation parameters. Then, the potential benefit of tadalafil in the prognosis of sepsis should be evaluated within a therapeutic strategy covering all sepsis injury mechanisms.
脓毒症是一种危及生命的病症,会影响心血管和肾脏系统。脓毒症期间的严重低血压会损害组织灌注,进而导致多器官功能障碍和死亡。磷酸二酯酶5(PDE5)可降解细胞内环磷酸鸟苷(cGMP)水平,从而促进特定部位的血管舒张。我们之前的研究表明,在脓毒症早期抑制cGMP生成会增加死亡率,这意味着cGMP生成具有保护作用。因此,我们推测他达拉非(一种PDE5抑制剂)增加的cGMP可改善微循环并预防脓毒症诱导的器官功能障碍。
将大鼠制成盲肠结扎穿孔(CLP)脓毒症模型,并在术后8小时用他达拉非(2毫克/千克,皮下注射)进行治疗。在诱导脓毒症24小时后进行血流动力学、炎症和生化评估。此外,评估他达拉非对脓毒症大鼠存活5天的影响。
他达拉非治疗可改善脓毒症期间的基础肾血流量,并在输注去甲肾上腺素期间维持该血流量。脓毒症除了会导致血浆一氧化氮和乳酸水平升高外,还会引起低血压、对去甲肾上腺素反应受损以及心脏和肾脏中性粒细胞浸润增加。他达拉非并未改变这些功能障碍中的任何一项。此外,他达拉非治疗并未提高脓毒症大鼠的存活率。
他达拉非改善了脓毒症动物的微循环;然而,在大循环和炎症参数方面未观察到有益效果。因此,应在涵盖所有脓毒症损伤机制的治疗策略中评估他达拉非在脓毒症预后方面的潜在益处。